Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Cisplatin, which is a chemotherapy used in this trial, is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib in combination with chemo-radiation may be better than chemo-radiation alone in treating patients with advanced head and neck cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histopatologicznie rak płaskonabłonkowy głowy i szyi (gardła, krtani, jamy ustnej lub innych okolic)
- •Wiek co najmniej 18 lat
- •Zdolność połykania tabletek w momencie włączenia do badania
- •Wynik testów krwi w normie (liczba białych krwinek, hemoglobina, płytki, funkcja wątroby i nerek)
- •Ogólny stan zdrowia pozwalający na chemioterapię i radioterapię
- •Oczekiwana przeżywalność dłuższa niż 3 miesiące
- •Test na wirusa HPV (dla określonych typów nowotworu)
✗ Disqualifies
- •Wiek poniżej 18 lat
- •Brak zdolności połykania tabletek
- •Poważne zaburzenia funkcji wątroby lub nerek
- •Niedostateczna liczba komórek krwi lub płytek krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (18)
Moffitt Cancer Center
Tampa, United States
Northwestern University
Chicago, United States
University of Kansas Clinical Research Center
Fairway, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
University of Kentucky/Markey Cancer Center
Lexington, United States
University of Maryland/Greenebaum Cancer Center
Baltimore, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Rutgers New Jersey Medical School
Newark, United States
Montefiore Medical Center-Einstein Campus
The Bronx, United States
Montefiore Medical Center - Moses Campus
The Bronx, United States
Carolinas Medical Center/Levine Cancer Institute
Charlotte, United States
Atrium Health Cabarrus/LCI-Concord
Concord, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, United States
University of Cincinnati Cancer Center-West Chester
West Chester, United States
University of Virginia Cancer Center
Charlottesville, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
University Health Network-Princess Margaret Hospital
Toronto, Canada
Trial contact
Site Public Contact
George Q. Yang
PRINCIPAL_INVESTIGATOR
Site Public Contact
Laila A. Gharzai
PRINCIPAL_INVESTIGATOR
Site Public Contact
Christopher Lominska
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ranee Mehra
PRINCIPAL_INVESTIGATOR
Site Public Contact
Malcolm D. Mattes
PRINCIPAL_INVESTIGATOR
Site Public Contact
Rafi Kabarriti
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jordan Kharofa
PRINCIPAL_INVESTIGATOR
Site Public Contact
Erin R. Alesi
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.